Summary
This study is looking at new ways to help prevent multiple myeloma from coming back after a stem cell transplant.
After a transplant, many people receive "maintenance treatment" (ongoing therapy to keep the cancer under control). The standard treatment is a drug called lenalidomide.
This trial is testing whether adding a newer targeted treatment called teclistamab, or using teclistamab on its own, works better than lenalidomide alone.
Who can take part?
You may be eligible if you have newly diagnosed multiple myeloma, have had initial treatment and a stem cell transplant, your cancer has responded to your first treatment (at least partially).
Study details
Eligible participants will be randomly assigned (by chance) to one of three treatment arms:
- Arm A: teclistamab with lenalidomide
- Arm B: lenalidomide alone
- Arm C: teclistamab alone